ambroxol has been researched along with Respiratory Tract Infections in 10 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " (4 x 300 mg, day 1-14), cefuroxime (CAS 55268-75-2) (2 x 250 mg daily for day 1-6), ambroxol (CAS 18683-91-5) (3 x 30 mg for day 1-3, 2 x 30 mg for days 4-14) and matched placebo in acute bronchitis." | 9.09 | Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. ( Carls, C; de Mey, C; Geib, A; Matthys, H; Ryś, A; Wittig, T, 2000) |
| "This paper was aimed at investigating the effects of bronchoalveolar lavage (BAL) with ambroxol hydrochloride (AH) on treating pulmonary infection and on serum proinflammatory cytokines and oxidative stress responses in patients with cerebral infarction (CI)." | 7.96 | Effects of Bronchoalveolar Lavage with Ambroxol Hydrochloride on Treating Pulmonary Infection in Patients with Cerebral Infarction and on Serum Proinflammatory Cytokines, MDA and SOD. ( Cheng, J; Meng, F; Sang, P; Wang, J, 2020) |
| "Rengalin liquid formulation on the basis of antibodies to bradikinin histamine and morphine was specially designed for the treatment of cough in children." | 5.19 | [Rengalin, a novel drug for treatment of cough in children. Intermediate data on multicentre, comparative randomized clinical trial]. ( Baltserovich, NB; Galustyan, AN; Geppe, NA; Kamaev, AV; Kondyurina, EG; Laleko, SL; Lazareva, SG; Melnikova, IM; Mikhalkova, EV; Pak, TE; Perminova, OA; Sabitov, AU; Spivakovsky, YM; Zhiglinskaya, OV, 2014) |
| " (4 x 300 mg, day 1-14), cefuroxime (CAS 55268-75-2) (2 x 250 mg daily for day 1-6), ambroxol (CAS 18683-91-5) (3 x 30 mg for day 1-3, 2 x 30 mg for days 4-14) and matched placebo in acute bronchitis." | 5.09 | Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. ( Carls, C; de Mey, C; Geib, A; Matthys, H; Ryś, A; Wittig, T, 2000) |
| "This paper was aimed at investigating the effects of bronchoalveolar lavage (BAL) with ambroxol hydrochloride (AH) on treating pulmonary infection and on serum proinflammatory cytokines and oxidative stress responses in patients with cerebral infarction (CI)." | 3.96 | Effects of Bronchoalveolar Lavage with Ambroxol Hydrochloride on Treating Pulmonary Infection in Patients with Cerebral Infarction and on Serum Proinflammatory Cytokines, MDA and SOD. ( Cheng, J; Meng, F; Sang, P; Wang, J, 2020) |
| "Results." | 2.79 | [Therapeutic modalities for the management of cough associated with acute respiratory viral infection, effective in an otolaryngologist's practice]. ( Korostelev, SA; Mitiuk, AM; Ovchinnikov, AI; Paniakina, MA, 2014) |
| "Treatment with ambroxol, but not carbocisteine, significantly reduced the median number of AURD episodes (P=0." | 2.72 | Ambroxol for the prevention of acute upper respiratory disease. ( Fujimura, M; Ishiura, Y; Myou, S; Nakao, S; Nobata, K, 2006) |
| "Symptoms of mild acute respiratory infections are commonly treated with over-the-counter products like ambroxol, bromhexine, and N-acetyl cysteine, as well as of thyme and pelargonium extracts today." | 1.56 | Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts. ( Döring, K; Schmidtke, M; Walther, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, F | 1 |
| Cheng, J | 1 |
| Sang, P | 1 |
| Wang, J | 1 |
| Walther, C | 1 |
| Döring, K | 1 |
| Schmidtke, M | 1 |
| Lu, Q | 1 |
| Yu, J | 1 |
| Bao, L | 1 |
| Ran, T | 1 |
| Zhong, H | 1 |
| Cataldi, M | 1 |
| Sblendorio, V | 1 |
| Leo, A | 1 |
| Piazza, O | 1 |
| Ovchinnikov, AI | 1 |
| Paniakina, MA | 1 |
| Korostelev, SA | 1 |
| Mitiuk, AM | 1 |
| Geppe, NA | 1 |
| Kondyurina, EG | 1 |
| Galustyan, AN | 1 |
| Pak, TE | 1 |
| Baltserovich, NB | 1 |
| Zhiglinskaya, OV | 1 |
| Kamaev, AV | 1 |
| Lazareva, SG | 1 |
| Laleko, SL | 1 |
| Melnikova, IM | 1 |
| Mikhalkova, EV | 1 |
| Perminova, OA | 1 |
| Sabitov, AU | 1 |
| Spivakovsky, YM | 1 |
| Nobata, K | 1 |
| Fujimura, M | 1 |
| Ishiura, Y | 1 |
| Myou, S | 1 |
| Nakao, S | 1 |
| Matthys, H | 1 |
| de Mey, C | 1 |
| Carls, C | 1 |
| Ryś, A | 1 |
| Geib, A | 1 |
| Wittig, T | 1 |
| Yang, B | 1 |
| Yao, DF | 1 |
| Ohuchi, M | 1 |
| Ide, M | 1 |
| Yano, M | 1 |
| Okumura, Y | 1 |
| Kido, H | 1 |
| Lauriello, G | 1 |
| Giella, D | 1 |
| Berra, A | 1 |
| Matonti, V | 1 |
1 review available for ambroxol and Respiratory Tract Infections
| Article | Year |
|---|---|
Biofilm-dependent airway infections: a role for ambroxol?
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Biofilms; Drug Resistance, Microbial; Expectorants; Hum | 2014 |
5 trials available for ambroxol and Respiratory Tract Infections
| Article | Year |
|---|---|
[Therapeutic modalities for the management of cough associated with acute respiratory viral infection, effective in an otolaryngologist's practice].
Topics: Acute Disease; Adult; Albuterol; Ambroxol; Bromhexine; Bronchodilator Agents; Cough; Drug Combinatio | 2014 |
[Rengalin, a novel drug for treatment of cough in children. Intermediate data on multicentre, comparative randomized clinical trial].
Topics: Administration, Oral; Adolescent; Ambroxol; Antibodies, Neutralizing; Antitussive Agents; Bradykinin | 2014 |
Ambroxol for the prevention of acute upper respiratory disease.
Topics: Aged; Aged, 80 and over; Alanine; Ambroxol; Carbocysteine; Female; Humans; Male; Quinolones; Respira | 2006 |
Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambroxol; Bronchitis; Bronchodilator Agents; Cefuroxime; Cep | 2000 |
[Combination of oral bacterial vaccines and antibiotics in acute recurrent respiratory infections].
Topics: Acute Disease; Administration, Oral; Adult; Ambroxol; Bacterial Vaccines; Bromhexine; Ceftriaxone; C | 1990 |
4 other studies available for ambroxol and Respiratory Tract Infections
| Article | Year |
|---|---|
Effects of Bronchoalveolar Lavage with Ambroxol Hydrochloride on Treating Pulmonary Infection in Patients with Cerebral Infarction and on Serum Proinflammatory Cytokines, MDA and SOD.
Topics: Ambroxol; Bronchoalveolar Lavage; Case-Control Studies; Cerebral Infarction; Computational Biology; | 2020 |
Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.
Topics: Acetylcysteine; Ambroxol; Animals; Bromhexine; Dogs; HeLa Cells; Humans; Influenza A virus; Madin Da | 2020 |
Effects of combined treatment with ambroxol and ciprofloxacin on catheter-associated Pseudomonas aeruginosa biofilms in a rat model.
Topics: Ambroxol; Animals; Anti-Bacterial Agents; Biofilms; Catheters; Ciprofloxacin; Disease Models, Animal | 2013 |
Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels.
Topics: Ambroxol; Animals; Bronchoalveolar Lavage Fluid; Cytokines; Expectorants; Immunoglobulins; Mice; Ort | 2002 |